Emergent BioSolutions (NYSE: EBS) director sells shares, receives new awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Emergent BioSolutions director Kathryn C. Zoon reported routine equity compensation and related share sales. On April 30, 2026, she received 25,344 restricted stock units for Board and Committee service and 11,296 stock options with a $7.99 exercise price, both vesting the day before the one-year grant anniversary, subject to continued board service.
On May 1, 2026, she sold a total of 17,202 shares of common stock in open-market transactions at weighted average prices of $8.36 and $8.97 per share under a Rule 10b5-1 trading plan dated May 16, 2025, to satisfy tax obligations from RSUs vesting on April 29, 2026. After these transactions, she directly holds 79,941 common shares.
Positive
- None.
Negative
- None.
Insights
Routine director equity awards with tax-related share sales under a 10b5-1 plan.
Emergent BioSolutions director Kathryn C. Zoon received 25,344 RSUs and 11,296 stock options at an exercise price of $7.99 for Board and Committee service. These awards vest on the day before the one-year anniversary of the April 30, 2026 grant date, contingent on continued board membership.
She sold 17,202 common shares at weighted average prices of $8.36 and $8.97 per share on May 1, 2026. Footnotes state the sales were executed under a Rule 10b5-1 trading plan to cover tax obligations tied to RSU vesting on April 29, 2026, which indicates a mechanistic, tax-driven disposition rather than a discretionary directional trade.
Following these transactions, she holds 79,941 common shares directly and 11,296 unvested options. The mix of new awards and tax-related sales, together with the pre-arranged trading plan, supports interpreting this Form 4 as routine compensation and portfolio maintenance rather than a thesis-changing signal.
Insider Trade Summary 10b5-1
Net Seller: 17,202 shares ($144,453)
Net Sell
4 txns
Insider
Zoon Kathryn C
Role
null
Sold
17,202 shs ($144K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 16,145 | $8.36 | $135K |
| Sale | Common Stock | 1,057 | $8.97 | $9K |
| Grant/Award | Stock Option (Right to Buy) | 11,296 | $0.00 | -- |
| Grant/Award | Common Stock | 25,344 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 80,998 shares (Direct, null);
Stock Option (Right to Buy) — 11,296 shares (Direct, null)
Footnotes (1)
- Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.77 to $8.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.79 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Key Figures
RSU grant: 25,344 shares
Stock options granted: 11,296 options at $7.99
Shares sold: 17,202 shares
+4 more
7 metrics
RSU grant
25,344 shares
Annual RSU award for Board and Committee service on April 30, 2026
Stock options granted
11,296 options at $7.99
Director stock options granted April 30, 2026; exercise price per share
Shares sold
17,202 shares
Common stock sold May 1, 2026 in open-market transactions
Weighted avg sale price 1
$8.36 per share
16,145 shares sold May 1, 2026; weighted average price
Weighted avg sale price 2
$8.97 per share
1,057 shares sold May 1, 2026; weighted average price
Post-transaction holdings
79,941 shares
Common shares directly held after reported transactions
Sale price ranges
$7.77–$8.70 and $8.79–$8.99
Price ranges for multiple executions underlying weighted averages
Key Terms
restricted stock units ("RSUs"), Rule 10b5-1 trading plan, weighted average price, Stock Incentive Plan, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Rule 10b5-1 trading plan regulatory
"Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price for sales executed on the same day"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Incentive Plan financial
"granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service"
A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.
Black-Scholes value financial
"dividing by the Black-Scholes value of a single option calculated as of the date of the grant"
FAQ
What insider transactions did EBS director Kathryn C. Zoon report?
Kathryn C. Zoon reported receiving 25,344 restricted stock units and 11,296 stock options, then selling 17,202 Emergent BioSolutions common shares. The sales occurred in open-market transactions shortly after the equity awards and were linked to tax obligations from RSU vesting.
What equity awards did Kathryn C. Zoon receive from Emergent BioSolutions (EBS)?
She received 25,344 restricted stock units and 11,296 stock options for Board and Committee service. Each RSU and option relates to one common share, with the options carrying a $7.99 exercise price and vesting on the day before the one-year anniversary of the grant date.
What is the vesting schedule for Kathryn C. Zoon’s new RSUs and options at EBS?
Both the 25,344 RSUs and 11,296 stock options vest on the day prior to the one-year anniversary of the April 30, 2026 grant date. Vesting is conditioned on Zoon remaining a member of Emergent BioSolutions’ board of directors through that Annual Grant Vesting Date.